Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||renal cell carcinoma||not applicable||SRF388||Preclinical||Actionable||In a preclinical study, SRF388 treatment demonstrated antitumor activity in an orthotopic mouse model of renal cell carcinoma (AACR 2020, Therapeutic Antibodies 3; PO.IM02.25, Abs nr: 4550/18).||detail...|
|PubMed Id||Reference Title||Details|
|Increased IL-27 is associated with poor prognosis in renal cell carcinoma and supports use of SRF388, a first-in-class IL-27p28 blocking antibody, to counteract IL-27-mediated immunosuppression in this setting||Full reference...|